AEGLEA BIOTHERAPEUTICS INC's ticker is AGLE and the CUSIP is 00773J103. A total of 33 filers reported holding AEGLEA BIOTHERAPEUTICS INC in Q3 2017. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $625 | +55.5% | 1,391,381 | 0.0% | 0.00% | +50.0% |
| Q1 2023 | $402 | -35.7% | 1,391,381 | 0.0% | 0.00% | -33.3% |
| Q4 2022 | $625 | -99.7% | 1,391,381 | +196.9% | 0.00% | +200.0% |
| Q3 2022 | $245,000 | +17.8% | 468,558 | +13.3% | 0.00% | 0.0% |
| Q2 2022 | $208,000 | -39.2% | 413,387 | +176.7% | 0.00% | 0.0% |
| Q1 2022 | $342,000 | -44.8% | 149,399 | +14.2% | 0.00% | -50.0% |
| Q4 2021 | $620,000 | +798.6% | 130,835 | +1426.7% | 0.00% | – |
| Q1 2019 | $69,000 | -86.7% | 8,570 | -84.2% | 0.00% | -100.0% |
| Q3 2018 | $519,000 | -32.9% | 54,230 | -25.8% | 0.00% | -33.3% |
| Q2 2018 | $773,000 | +151.8% | 73,100 | +136.9% | 0.00% | +200.0% |
| Q1 2018 | $307,000 | +468.5% | 30,860 | +206.4% | 0.00% | – |
| Q4 2017 | $54,000 | +145.5% | 10,073 | +121.2% | 0.00% | – |
| Q3 2017 | $22,000 | +1000.0% | 4,554 | +840.9% | 0.00% | – |
| Q4 2016 | $2,000 | – | 484 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Yu Fan | 112,044 | $532,000 | 6.17% |
| Aisling Capital Management LP | 1,691,151 | $8,033,000 | 2.83% |
| Bain Capital Life Sciences Investors, LLC | 2,847,689 | $13,527,000 | 1.07% |
| GREAT POINT PARTNERS LLC | 910,251 | $4,324,000 | 0.96% |
| Samsara BioCapital, LLC | 883,720 | $4,198,000 | 0.81% |
| Sio Capital Management, LLC | 498,500 | $2,368,000 | 0.71% |
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 245,678 | $1,167,000 | 0.53% |
| Nantahala Capital Management | 2,813,560 | $13,364,000 | 0.47% |
| Altium Capital Management LP | 293,764 | $1,395,000 | 0.38% |
| Lion Point Capital, LP | 300,000 | $1,425,000 | 0.38% |